The Week That Was, The Week Ahead: Macro and Markets, April 26
at www.tipranks.com (Sun, 26-Apr 4:42 AM)
Novo Nordisk Tracks Real-World Refixia® Use In Japan: What Investors Should Watch
at www.tipranks.com (Sat, 25-Apr 12:30 PM)
Now Is the Time to Buy Hims & Hers Stock (HIMS), Says JPMorgan Chase
at www.tipranks.com (Fri, 24-Apr 11:11 AM)
Hims rises as J.P. Morgan initiates at Overweight on rich catalyst path
at seekingalpha.com (Fri, 24-Apr 10:15 AM)
Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy
at seekingalpha.com (Fri, 24-Apr 8:10 AM)
Eli Lilly (LLY) Expands Partnership with Hims & Hers
at www.tipranks.com (Thu, 23-Apr 3:27 PM)
Novo Nordisk Completes Key CagriSema vs. Tirzepatide Diabetes Trial: What Investors Should Watch
at www.tipranks.com (Thu, 23-Apr 12:31 PM)
4 stocks to watch on Thursday: HON, LULU, NVO, BX
at seekingalpha.com (Thu, 23-Apr 8:54 AM)
Novo to launch Ozempic pill for children after late-stage trial win
at seekingalpha.com (Thu, 23-Apr 7:32 AM)
Novo Nordisk (NVO) Scores Pediatric GLP-1 Win, but Stock Stays Flat
at www.tipranks.com (Thu, 23-Apr 7:31 AM)
Hims & Hers (HIMS) Gets Good News from the FDA. Is It Already Priced in?
at www.tipranks.com (Thu, 23-Apr 6:07 AM)
Medicare delays GLP-1 coverage plan; interim program extended
at seekingalpha.com (Wed, 22-Apr 9:19 AM)
Market Chameleon (Fri, 20-Mar 11:00 AM)
Market Chameleon (Fri, 20-Mar 7:07 AM)
